KalVista Pharmaceuticals, Inc.
KALV · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.46 | -0.23 | -2.20 | -0.62 |
| FCF Yield | -7.47% | -5.85% | -7.00% | -8.31% |
| EV / EBITDA | -10.35 | -13.90 | -7.47 | -9.74 |
| Quality | ||||
| ROIC | -34.15% | -26.08% | -18.69% | -32.67% |
| Gross Margin | 58.63% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.66 | 0.91 | 0.77 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,472,562.15% | 1,125,471.73% | -100.00% | -100.00% |
| Free Cash Flow Growth | -36.21% | -21.96% | 17.66% | 0.99% |
| Safety | ||||
| Net Debt / EBITDA | 2.00 | 2.17 | 3.92 | 0.78 |
| Interest Coverage | -16.75 | -18.70 | -15.11 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -773.71 | 1,961.92 | 0.00 | 0.00 |